Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Regina Swift"'
Autor:
Ryan Danis, Bernard Regidor, Sean Bujarski, Scott Jew, Marissa-Skye Goldwater, Regina Swift, Benjamin Mark Eades, Marsiye Emamy-Sadr, Ashley Del Dosso, James Berenson
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 747-752 (2024)
Introduction: Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda serum free light chains (sFLCs) at diagnosis. Ho
Externí odkaz:
https://doaj.org/article/6ae75aed914b4d0096b6180e5be82841
Autor:
Samuel D. Stampfer, Sean Bujarski, Marissa‐Skye Goldwater, Scott Jew, Bernard Regidor, Haiming Chen, Ning Xu, Mingjie Li, Eddie Fung, Regina Swift, Bethany Beatty, Shahrooz Eshaghian, James R. Berenson
Publikováno v:
Cancer Reports, Vol 6, Iss 5, Pp n/a-n/a (2023)
Abstract Background Multiple myeloma (MM) patients have variable responses to mRNA vaccination to COVID‐19. Little is known regarding their vaccine‐induced antibody levels over time. Methods We monitored spike IgG antibody levels over 24 weeks am
Externí odkaz:
https://doaj.org/article/bb9ad0d3dbb24064b8f3ae5394852ffe
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 3, Pp 1103-1108 (2020)
A 52-year-old African-American woman with a prior history of monoclonal gammopathy of undetermined significance (MGUS) developed infiltrating ductal carcinoma of the left breast. Following a mastectomy, she underwent reconstruction with a silicone ge
Externí odkaz:
https://doaj.org/article/826fbfe1a7a841b68084ea08d94f9e16
Autor:
Samuel D. Stampfer, Marissa-Skye Goldwater, Sean Bujarski, Bernard Regidor, Wenjuan Zhang, Aaron J. Feinstein, Regina Swift, Shahrooz Eshaghian, Eric Vail, James R. Berenson
Publikováno v:
Clinical Infection in Practice, Vol 13, Iss , Pp 100130- (2022)
Background: Patients with multiple myeloma have unpredictable responses to vaccination for COVID-19. Anti-spike antibody levels can determine which patients develop antibodies at levels similar to healthy controls, and are a known correlate of protec
Externí odkaz:
https://doaj.org/article/8dfc4853844b41d6a5030489015e8d31
Autor:
Samuel D. Stampfer, Sean Bujarski, Marissa‐Skye Goldwater, Scott Jew, Bernard Regidor, Haiming Chen, Ning Xu, Mingjie Li, Eddie Fung, Regina Swift, Bethany Beatty, Shahrooz Eshaghian, James R. Berenson
Publikováno v:
Cancer Reports. 6
Autor:
Bernard Sean Regidor, Dilawer Siddiqi, Bethany Marie Beatty, Marissa‐Skye Goldwater, Scott Jew, Sean Bujarski, Regina Swift, Susanna Kim, James R. Berenson
Publikováno v:
European Journal of Haematology. 110:222-223
Autor:
Bernard, Regidor, Regina, Swift, Benjamin, Eades, Marsiye, Emamy-Sadr, Fadi, Tarhini, Tanya M, Spektor, James R, Berenson
Publikováno v:
Annals of hematology. 100(4)
The purpose of this single-center retrospective study was to determine the incidence of decreased blood phosphorus levels and hypophosphatemia among multiple myeloma (MM) patients treated with elotuzumab. Hypophosphatemia, which is defined as a serum
Autor:
James R. Berenson, Daisy Martinez, Tahmineh Safaie, Noemi Silagan, Jennifer To, Tanya M. Spektor, Eli Forouzan, Regina Swift, Benjamin Eades, Shahrooz Eshaghian, Gary Schwartz, Ralph V. Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Robert Vescio
Publikováno v:
Blood. 138:2727-2727
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with intermediate or high-risk myelofibrosis and polycythemia vera who have had an inadequate response to or are intol
Autor:
James R. Berenson, Jennifer To, Tanya M. Spektor, Daisy Martinez, Armando J. Sanchez, Carley Turner, Regina Swift, Benjamin Eades, Gary Schwartz, Shahrooz Eshaghian, Laura V. Stampleman, Robert A. Moss, Youram Nassir, Ravindranath Patel, Alberto Bessudo, Daniel Greenwald, Ralph V. Boccia, Stephen Lim, Robert Vescio
Publikováno v:
Blood. 134:1903-1903
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea or intermediate or high
Publikováno v:
Clinical Journal of Oncology Nursing. 7:403-408
The knowledge and training of nursing staff is essential for the safety and comfort of patients receiving i.v. therapies. The use of i.v. bisphosphonates as an adjunct to standard antineoplastic therapies in patients with advanced cancer is becoming